Larimar Therapeutics, Inc. (LRMR) |
| 5.31 -0.21 (-3.8%) 02-27 16:00 |
| Open: | 5.54 |
| High: | 5.6699 |
| Low: | 5.19 |
| Volume: | 4,267,734 |
| Market Cap: | 454(M) |
| PE Ratio: | -2.71 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 7.50 |
| Resistance 1: | 6.42 |
| Pivot price: | 3.67 |
| Support 1: | 4.13 |
| Support 2: | 2.71 |
| 52w High: | 6.42 |
| 52w Low: | 1.61 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Financials
| EPS | -1.960 |
| Book Value | 1.620 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -43.0 |
| Return on Equity (ttm) | -78.2 |
Company news
Fri, 27 Feb 2026
Larimar Therapeutics (LRMR) Is Up 85.9% After Breakthrough Status For Nomlabofusp In Friedreich’s Ataxia - simplywall.st
Fri, 27 Feb 2026
Larimar Therapeutics Prices $5.00 Public Offering, Nets ~$107.6 Million as Option Is Exercised - TradingView
Thu, 26 Feb 2026
Larimar Therapeutics Prices Upsized 20 Mln Public Offering At $5.00 Per Share, Stock Down - Nasdaq
Thu, 26 Feb 2026
Larimar Therapeutics (LRMR) Upsizes Public Offering to Raise $10 - GuruFocus
Wed, 25 Feb 2026
Larimar Therapeutics, Inc. Prices Upsized Public Offering of 20 Million Shares at $5.00 Each - Quiver Quantitative
Wed, 25 Feb 2026
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
